These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28413387)

  • 21. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps.
    Thomas RM; Colon A; Motaparthi K
    Clin Dermatol; 2020; 38(3):384-396. PubMed ID: 32563354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of rituximab in a case of refractory bullous pemphigoid].
    Reguiaï Z; Tchen T; Perceau G; Bernard P
    Ann Dermatol Venereol; 2009 May; 136(5):431-4. PubMed ID: 19442800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience.
    Aguado Vázquez Á; Estébanez Corrales A; Melgosa Ramos FJ; Mascaró Galy JM; Fulgencio-Barbarin J; Bosch Amate X; Curto Barredo L; Blanes-Martínez M; Ruiz-Villaverde R; Ballester Martínez A; Martín-Torregrosa D; Castaño Fernández JL; Cabeza Martínez R; Pérez-Ferriols A; Ramos Rodríguez D; Boix Vilanova J; Melé-Ninot G; Expósito Serrano V; España Alonso A; Mateu-Puchades A
    Clin Exp Dermatol; 2024 Aug; 49(9):1002-1006. PubMed ID: 38430106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
    van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
    JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Significance of Eosinophil-to-Lymphocyte Ratio in Predicting Response to Omalizumab Treatment in Patients with Bullous Pemphigoid: A Case Series.
    Akin G; Avci C; Akarsu S
    Indian J Dermatol; 2024; 69(1):81-85. PubMed ID: 38572025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Therapy of Plasma Exchange and Rituximab to Treat Cicatricial Pemphigoid and Bullous Pemphigoid.
    Kunadia A; Sami N
    Cureus; 2021 Nov; 13(11):e19932. PubMed ID: 34984113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dermatologic uses of omalizumabtitle.
    Chia JC; Mydlarski PR
    J Dermatolog Treat; 2017 Jun; 28(4):332-337. PubMed ID: 27759482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?
    Ujiie H
    J Dermatol Sci; 2015 Apr; 78(1):5-10. PubMed ID: 25797172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three cases of refractory bullous pemphigoid in the elderly treated successfully with ultra-low-dose rituximab.
    Chen Q; Hu B; Wan L; Hu L; Zhou X; Chen L; Chen J
    J Dermatol; 2023 Apr; 50(4):561-564. PubMed ID: 36539929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid.
    Le ST; Herbert S; Haughton R; Nava J; Toussi A; Ji-Xu A; Maverakis E
    JAMA Dermatol; 2024 Jan; 160(1):107-109. PubMed ID: 37991748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases.
    van Beek N; Schulze FS; Zillikens D; Schmidt E
    Expert Rev Clin Immunol; 2016; 12(3):267-77. PubMed ID: 26588556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-IgE antibodies for the treatment of asthma.
    Buhl R
    Curr Opin Pulm Med; 2005 Jan; 11(1):27-34. PubMed ID: 15591885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
    Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
    Front Immunol; 2018; 9():248. PubMed ID: 29520266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient.
    Navarro-Triviño FJ; Llamas-Molina JM; Ayen-Rodriguez A; Cancela-Díez B; Ruiz-Villaverde R
    Eur J Hosp Pharm; 2021 Nov; 28(6):350-352. PubMed ID: 32920533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G
    Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).
    D'Amato G; Bucchioni E; Oldani V; Canonica W
    Treat Respir Med; 2006; 5(6):393-8. PubMed ID: 17154668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients.
    J Am Acad Dermatol; ; . PubMed ID: 30923002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.